Logo image of RGC

REGENCELL BIOSCIENCE HOLDING (RGC) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:RGC - KYG7487R1002 - Common Stock

11.53 USD
+0.42 (+3.78%)
Last: 11/28/2025, 7:58:49 PM
12.31 USD
+0.78 (+6.76%)
After Hours: 11/28/2025, 7:58:49 PM

RGC Key Statistics, Chart & Performance

Key Statistics
Market Cap5.70B
Revenue(TTM)N/A
Net Income(TTM)-4.09M
Shares494.49M
Float56.59M
52 Week High83.6
52 Week Low0.09
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-07-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


RGC short term performance overview.The bars show the price performance of RGC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

RGC long term performance overview.The bars show the price performance of RGC in the last 1, 2 and 3 years. 1 year 2 years 3 years 2K 4K 6K

The current stock price of RGC is 11.53 USD. In the past month the price decreased by -29.48%. In the past year, price increased by 6832.59%.

REGENCELL BIOSCIENCE HOLDING / RGC Daily stock chart

RGC Latest News, Press Relases and Analysis

RGC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.91 1.02T
JNJ JOHNSON & JOHNSON 19.93 498.53B
MRK MERCK & CO. INC. 11.9 260.19B
PFE PFIZER INC 8.04 146.35B
BMY BRISTOL-MYERS SQUIBB CO 7.5 100.16B
ZTS ZOETIS INC 20.22 56.49B
RPRX ROYALTY PHARMA PLC- CL A 9.74 23.10B
VTRS VIATRIS INC 4.59 12.31B
ELAN ELANCO ANIMAL HEALTH INC 24.24 11.56B
CORT CORCEPT THERAPEUTICS INC 90.23 8.35B
AXSM AXSOME THERAPEUTICS INC N/A 7.64B
BLTE BELITE BIO INC - ADR N/A 4.80B

About RGC

Company Profile

RGC logo image Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Company Info

REGENCELL BIOSCIENCE HOLDING

11/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay

Hong Kong 37918 HK

CEO: Yat-Gai Au

Employees: 12

RGC Company Website

RGC Investor Relations

Phone: 85221550823

REGENCELL BIOSCIENCE HOLDING / RGC FAQ

What does RGC do?

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.


Can you provide the latest stock price for REGENCELL BIOSCIENCE HOLDING?

The current stock price of RGC is 11.53 USD. The price increased by 3.78% in the last trading session.


Does RGC stock pay dividends?

RGC does not pay a dividend.


How is the ChartMill rating for REGENCELL BIOSCIENCE HOLDING?

RGC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists RGC stock?

RGC stock is listed on the Nasdaq exchange.


How many employees does REGENCELL BIOSCIENCE HOLDING have?

REGENCELL BIOSCIENCE HOLDING (RGC) currently has 12 employees.


RGC Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to RGC. When comparing the yearly performance of all stocks, RGC is one of the better performing stocks in the market, outperforming 99.98% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RGC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RGC. RGC has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RGC Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA -54.68%
ROE -60.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)100%
Revenue 1Y (TTM)N/A

RGC Forecast & Estimates


Analysts
Analysts63.4
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

RGC Ownership

Ownership
Inst Owners0.14%
Ins Owners88.56%
Short Float %6.79%
Short Ratio7.07